Patient‐Reported Impact of Atopic Dermatitis on Pediatric and Adolescent Patients With Moderate‐To‐Severe Disease: Results of a Real‐World, Cross‐Sectional Survey

作者：Lawrence F. Eichenfield, Vivian Y. Shi, JiaDe Yu, Evangeline Pierce, Amber Reck Atwater, Jenny Austin, Peter Anderson, Amy S. Paller · 发表于：Pediatric Dermatology · 年份：2025 · DOI：10.1111/pde.15940 · 被引用次数：5 · 研究领域：Dermatology and Skin Diseases、Allergic Rhinitis and Sensitization、Food Allergy and Anaphylaxis Research

Atopic dermatitis (AD) is a common and burdensome disease. Treatment options for pediatric and adolescent patients (< 18 years old) with moderate-to-severe AD are limited, and real-world data on disease burden are lacking. This study examined patient-reported disease burden and treatments in pediatric and adolescent patients to identify opportunities for patient benefit. Data were drawn from the Adelphi Real World Pediatric AD Disease Specific Programme (DSP), a cross-sectional survey of physicians and patients < 18 years old, conducted in Europe and the United States between February-June 2019. Physicians documented demographics, clinical characteristics, and treatment history. Patients and/or their caregivers described disease burden, the degree of symptomatic bother, and quality of life (QoL). Data from 772 patients with moderate-to-severe AD were analyzed (pediatric; n = 393, 0-11 years, adolescent; n = 379, 12-17 years). Adolescents were more likely to be receiving a systemic corticosteroid (24% vs. 12%), phototherapy (15% vs. 6%), systemic immunosuppressant (15% vs. 6%) or a biologic treatment (5% vs. 1%) than pediatric patients (p < 0.0001). Two-thirds of patients had a high degree of "bother" from itch, and 38% reporting itch as the "most bothersome" symptom. More adolescent patients reported "bother" related to anxiety than pediatric patients (67% vs. 49%, p < 0.0001). Adolescent patients reported a significantly higher burden of embarrassment/self-consciousness (p <...